Summary

Overview
Global In-vitro Toxicology Testing Market reached US$ XX million in 2023 and is expected to reach US$ XX million by 2031, growing with a CAGR of XX % during the forecast period 2024-2031.
In vitro models play an important role in the toxicity testing of cosmetics, drugs and pharmaceutical therapies. Advancements in in vitro cell culture have given researchers a viable alternative and/or complement to live animal testing.
In vitro models offer several ethical and economic advantages over animal testing. These assays are being used earlier in toxicity testing pipelines, often to determine risk assessment and/or set up controls that will ultimately spare animal life. The combination of lower-cost and higher throughput assays can help bring products to market faster. Additionally, in vitro models give researchers an advantage in understanding the biological process involved in a toxic response sooner than if they were depending on the visual inspection of a live animal.
Market Dynamics: Drivers and Restraints
Rise in advancements in in-vitro toxicology testing
Technological advancements in in-vitro toxicology testing have made it a preferred method over animal testing. Regulatory agencies are increasingly validating and accepting these methods, boosting the market. In some countries, animal geno-toxicology testing is mandated before marketing certain consumer items, such as genetically modified foods, vaccines, devices, drugs, industrial chemicals, and pesticides.
Additionally, recent advancements in the understanding of stem cell-derived cardiomyocytes have allowed researchers to develop more accurate and reproducible in vitro assays that are based on human cells. Future work in this area hopes to use stem cell-derived cardiomyocytes that have been integrated into three-dimensional structures for an additional layer of drug safety screening.
Furthermore, the in-vitro toxicology testing market is also driven by various other factors like the rise in demand for healthcare services, rise in the government initiatives and others that help the market to grow during the forecast period.
Market Dynamics: Restraint
In vitro toxicity testing is gaining recognition due to animal testing bans in several countries. However, it still needs to demonstrate validity compared to in vivo tests. In vitro tests only determine the mechanism of action of test substances, not their outcomes after metabolism. Although a chemical substance may not be harmful, its metabolites can be detrimental.
Segment Analysis
The global in-vitro toxicology testing market is segmented based on product and service type, toxicity, technology, end-user and region.
The assays from the product and service type segment accounted for approximately 39.7% of the in-vitro toxicology testing market share
The assays from the product and service type segment accounted for approximately 39.7% and are expected to dominate during the forecast period. In vitro toxicity assays are some of the most useful preclinical methods of not only determining a drug’s safety profile but also providing an opportunity for researchers to improve its properties before reaching clinical trials.
In vitro toxicology assays, in silico and chemical testing approaches, are crucial in identifying alternative methods to traditional animal-based toxicity testing. These services support metabolic, toxicokinetic, and bioanalytical investigations with qualitative and quantitative data, promoting the 3Rs (Replacement, Reduction, and Refinement) approach.
Geographical Analysis
North America accounted for approximately 38.4% of the market share in 2022
North America is estimated to hold about 38.4% of the total market share throughout the forecast period owing to the factors like acquisitions by companies, rising government funding for research of therapeutics, increased healthcare expenditure, advanced infrastructure & processes for drug discovery and strong regulatory framework for approval has increased the demand as well as adoption on in-vitro testing methods in this region’s market.
For instance, in March 2023, Agilent Technologies, Inc. (US) acquired e-MSion (US). Through this acquisition, Agilent will integrate the e-MSion's ExD cell into its portfolio of advanced workflows, instruments, and analytical solutions for biotherapeutic characterization and development.
Moreover, in September 2022, ioIVT disclosed the successful acquisition of XenoTech, showcasing its dedication to offering extensive research models and services to biopharmaceutical customers for improved drug development and diagnostic research.
COVID-19 Impact Analysis
The COVID-19 pandemic had a substantial impact on the overall market resulting in limitations of movement and restrictions due to which the market observed a short-term decline in growth. However, as there were multiple drug discovery processes, various drug development programs & and high research activities, the market demand for in-vitro toxicology testing accelerated eventually.
Market Segmentation
By Product & Service Type
• Assays
o Bacterial Toxicity Assays
o Enzyme Toxicity Assays
o Cell-Based ELISA & Western Blotting Assays
o Receptor Binding Assays
o Others
• Consumables
• Services
• Equipment’s
• Software
By Toxicity
• Cytotoxicity
• Gene Toxicity
• Cardiotoxicity
• Hepatotoxicity
• Ophthalmic Toxicity
• Others
By Technology
• Cell Culture
• High Throughput Screening
• Toxicogenomics
By End User
• Pharmaceutical and Biopharmaceutical Companies
• Consumer Care and Food Industry
• Others
By Region
• North America
o U.S.
o Canada
o Mexico
• Europe
o Germany
o UK
o France
o Italy
o Spain
o Rest of Europe
• South America
o Brazil
o Argentina
o Rest of South America
• Asia-Pacific
o China
o India
o Japan
o Australia
o Rest of Asia-Pacific
• Middle East and Africa
Competitive Landscape
The major global players in the market include Charles River Laboratories International, Inc., SGS S.A., Eurofins Scientific, Laboratory Corporation of America Holdings, Evotec S.E., Agilent Technologies, Inc., Catalent, Inc., Bio-Rad Laboratories, Inc., BioIVT, Gentronix and among others.
Key Developments
 In January 2023, Eurofins Scientific expanded its presence in India with the establishment of a new, fully equipped, state-of-the-art laboratory campus in Genome Valley, Hyderabad. The lab will support pharma and biotech companies in the areas of synthetic organic chemistry, analytical R&D, bioanalytical services, in vivo pharmacology, safety toxicology, and formulation R&D.
 In January 2021, Charles River stated a partnership with Cypre, Inc., for the expansion of services of 3D in-vitro models for immunotherapy treatment of cancer as well as targeted therapy drug screening. This partnership enabled the company to access Cypre’s patented 3D hydrogel technology or Falcon-X to expand Charles River’s services.
Why Purchase the Report?
• To visualize the global in-vitro toxicology testing market segmentation based on product and service type, toxicity, technology, end-user and region as well as understand key commercial assets and players.
• Identify commercial opportunities by analyzing trends and co-development.
• Excel data sheet with numerous data points of in-vitro toxicology testing market-level with all segments.
• PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
• Product mapping available as excel consisting of key products of all the major players.
The global in-vitro toxicology testing market report would provide approximately 69 tables, 70 figures and 183 pages.
Target Audience 2023
• Manufacturers/ Buyers
• Industry Investors/Investment Bankers
• Research Professionals
• Emerging Companies

ページTOPに戻る

Table of Contents

1. Methodology and Scope
1.1. Research Methodology
1.2. Research Objective and Scope of the Report
2. Definition and Overview
3. Executive Summary
3.1. Snippet by Product and Service Type
3.2. Snippet by Toxicity
3.3. Snippet by Technology
3.4. Snippet by End User
3.5. Snippet by Region
4. Market Dynamics
4.1. Impacting Factors
4.1.1. Drivers
4.1.1.1. Rise in advancements in in-vitro toxicology testing
4.1.1.2. Rise in the government initiatives
4.1.2. Restraints
4.1.2.1. Regulatory Challenges
4.1.3. Opportunity
4.1.4. Impact Analysis
5. Industry Analysis
5.1. Porter's Five Force Analysis
5.2. Supply Chain Analysis
5.3. Pricing Analysis
5.4. Regulatory Analysis
5.5. Unmet Needs
5.6. DMI Opinion
6. COVID-19 Analysis
6.1. Analysis of COVID-19
6.1.1. Scenario Before COVID
6.1.2. Scenario During COVID
6.1.3. Scenario Post COVID
6.2. Pricing Dynamics Amid COVID-19
6.3. Demand-Supply Spectrum
6.4. Government Initiatives Related to the Market During Pandemic
6.5. Manufacturers' Strategic Initiatives
6.6. Conclusion
7. By Product and Service Type
7.1. Introduction
7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product and Service Type
7.1.2. Market Attractiveness Index, By Product and Service Type
7.2. Assays *
7.2.1. Introduction
7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
7.3. Consumables
7.4. Equipment
7.5. Services
7.6. Software
8. By Toxicity
8.1. Introduction
8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Toxicity
8.1.2. Market Attractiveness Index, By Toxicity
8.2. Cytotoxicity *
8.2.1. Introduction
8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
8.3. Gene Toxicity
8.4. Cardiotoxicity
8.5. Hepatotoxicity
8.6. Ophthalmic Toxicity
8.7. Others
9. By Technology
9.1. Introduction
9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology
9.1.2. Market Attractiveness Index, By Technology
9.2. Cell Culture*
9.2.1. Introduction
9.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
9.3. High Throughput Screening
9.4. Toxicogenomics
10. By End User
10.1. Introduction
10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
10.1.2. Market Attractiveness Index, By End User
10.2. Pharmaceutical and Biopharmaceutical Companies*
10.2.1. Introduction
10.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
10.3. Consumer Care and Food Industry
10.4. Others
11. By Region
11.1. Introduction
11.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
11.1.2. Market Attractiveness Index, By Region
11.2. North America
11.2.1. Introduction
11.2.2. Key Region-Specific Dynamics
11.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product and Service Type
11.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Toxicity
11.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology
11.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
11.2.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
11.2.7.1. The U.S.
11.2.7.2. Canada
11.2.7.3. Mexico
11.3. Europe
11.3.1. Introduction
11.3.2. Key Region-Specific Dynamics
11.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product and Service Type
11.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Toxicity
11.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology
11.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
11.3.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
11.3.7.1. Germany
11.3.7.2. UK
11.3.7.3. France
11.3.7.4. Italy
11.3.7.5. Spain
11.3.7.6. Rest of Europe
11.4. South America
11.4.1. Introduction
11.4.2. Key Region-Specific Dynamics
11.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product and Service Type
11.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Toxicity
11.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology
11.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
11.4.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
11.4.7.1. Brazil
11.4.7.2. Argentina
11.4.7.3. Rest of South America
11.5. Asia-Pacific
11.5.1. Introduction
11.5.2. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product and Service Type
11.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Toxicity
11.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology
11.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
11.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
11.5.6.1. China
11.5.6.2. India
11.5.6.3. Japan
11.5.6.4. Australia
11.5.6.5. Rest of Asia-Pacific
11.6. Middle East and Africa
11.6.1. Introduction
11.6.2. Key Region-Specific Dynamics
11.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product and Service Type
11.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Toxicity
11.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology
11.6.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
12. Competitive Landscape
12.1. Competitive Scenario
12.2. Market Positioning/Share Analysis
12.3. Mergers and Acquisitions Analysis
13. Company Profiles
13.1. Charles River Laboratories International, Inc.*
13.1.1. Company Overview
13.1.2. Product Portfolio and Description
13.1.3. Financial Overview
13.1.4. Key Developments
13.2. SGS S.A.
13.3. Eurofins Scientific
13.4. Laboratory Corporation of America Holdings
13.5. Evotec S.E.
13.6. Agilent Technologies, Inc.
13.7. Catalent, Inc.
13.8. Bio-Rad Laboratories, Inc.
13.9. BioIVT
13.10. Gentronix
LIST NOT EXHAUSTIVE
14. Appendix
14.1. About Us and Services
14.2. Contact Us